AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00017290
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00146380
Drug: Zidovudine/Lamivudine and either Nevirapine or Nelfinavir
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine 300mg po bid from 34 weeks gestation to 6 months postpartum Lamivudine 150mg po bid from 34 weeks gestation to 6 months postpartum AND EITHER Nevirapine 200mg po qd for 2 weeks as lead in then bid from 34 weeks gestation to 6 months postpartum OR Nelfinavir 1250mg po bid from 34 weeks gestation to 6 months postpartum~ARVs continued for those that meet WHO treatment criteria
Trial: NCT03150628
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy
Trial: NCT00136552
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02795325
Drug: DCR-PH1
RxNorm normalized name: DCR-PH1
DrugBank: DCR-PH1 (DB17663)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of DCR-PH1
Trial: NCT02868229
Drug: COR-001
RxNorm normalized name: Aspi-Cor
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02764684
Drug: Probiotic
RxNorm normalized name: PROBIOTIC
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The probiotic strain Lactobacillus rhamnosus will be self-administrated twice a day, one capsule in the morning and one in the evening for eight weeks.
Trial: NCT00875342
Drug: DCS
RxNorm normalized name: DCS
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Cognitive behavioral treatment with exposure therapy plus D-Cycloserine (100 mg on days of therapy session (approximately 9 times)
Trial: NCT03204253
Drug: rFSH alone
RxNorm normalized name: rFSH-alpha
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 32 women who were stimulated with recombinant FSH alone
Trial: NCT00367276
Drug: Yasmin (30 µg EE, 3 mg Drospirenone, BAY86-5131)
RxNorm normalized name: drospirenone
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Yasmin, SH T 470 FA; 30 µg ethinylestradiol and 3 mg drospirenone, oral administration over 6 treatment cycles, one tablet per day for 21 days followed by a 7 day pill-free interval.
Trial: NCT03848767
Drug: Insulin Lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Individualized doses of insulin lispro administered via the AID system to maintain glycemic control except during meal challenges.
Trial: NCT01656070
Drug: oral cholecalciferol 1000000 UI (vitamin D3)
RxNorm normalized name: cholecalciferol Oral Capsule
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01141478
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg po bid
Trial: NCT01278082
Drug: Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Alternating daily dosing with 2 x 3 mg budesonide capsules OD and 1 x 3 mg budesonide capsule OD every second day
Trial: NCT01493882
Drug: JNJ-39758979 30 mg/d
DrugBank: JNJ-39758979 (DB18899)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unit = mg, number = 30, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
Trial: NCT01641822
Drug: AZLI
RxNorm normalized name: Bazlitoran
DrugBank: Bazlitoran (DB14990)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam for Inhalation Solution (AZLI) 75 mg 3 times daily combined with diluent administered using an eFlow nebulizer
Trial: NCT01641822
Drug: Tobramycin inhalation solution
RxNorm normalized name: Tobramycin Inhalation Solution
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin inhalation solution (TIS) 300 mg 2 times daily using a PARI® LC Plus nebulizer and DeVilbiss Pulmo-Aide® air compressor
Trial: NCT00454584
Drug: CNTO 1275 45 mg
RxNorm normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
DrugBank: Carlumab (DB12718)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact number, number=45, unit=mg, form=injection, route=subcutaneous
Trial: NCT00454584
Drug: CNTO 1275 90 mg
RxNorm normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
DrugBank: Carlumab (DB12718)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact number, number=90, unit=mg, form=injection, route=subcutaneous
Trial: NCT00454584
Drug: Etanercept 50 mg
RxNorm normalized name: etanercept 50 MG/ML
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Type=exact number, number=50, unit=mg, form=injection, route=subcutaneous
Trial: NCT00143377
Drug: tolterodine SR, overactive bladder
DrugBank: Tolterodine (DB01036)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04467125
Drug: Eutectic Lidocaine Prilocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects randomized to EMLA receive one inch of EMLA cream placed at the removal site and then have an occlusive dressing placed. One hour later they have the Nexplanon device removed.
Trial: NCT04467125
Drug: Subcutaneous Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects randomized to subcutaneous lidocaine have 1% lidocaine injected by the provider at the removal site in an amount decided on by the provider.
Trial: NCT00820872
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00820872
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00820872
Drug: lapatinib ditosylate
RxNorm normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02251210
Drug: BIIL 284 BS low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02251210
Drug: BIIL 284 BS medium dose
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02251210
Drug: BIIL 284 BS high dose
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04122170
Drug: Ticagrelor Oral Tablet - Pre-Treatment
RxNorm normalized name: ticagrelor Oral Tablet
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg oral tablet; administered as 180 mg (2 × 90 mg tablet) loading dose plus 90 mg every 12 hours for 4 additional doses.
Trial: NCT04122170
Drug: Bentracimab (PB2452) Infusion
RxNorm normalized name: Duo Fusion
DrugBank: Bentracimab (DB16659)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration~In subjects with potential drug interaction from concomitant use of moderate or strong CYP3A inhibitors with ticagrelor, the active treatment period may be 24 hours and 10 min if receiving the 36 g infusion.
Trial: NCT00294255
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: risperidone will be administered 1-3mg pills, each night, for up to 20 weeks
Trial: NCT03957876
Drug: CPX-351
RxNorm normalized name: CPX
DrugBank: DPCPX (DB12946)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin.
Trial: NCT03847909
Drug: DCR-PHXC
RxNorm normalized name: DCR-PHXC free acid
DrugBank: Nedosiran (DB17635)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection
Trial: NCT03847909
Drug: Sterile Normal Saline (0.9% NaCl)
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile Normal Saline (0.9% NaCl) for subcutaneous (SC) injection, administered at same injection volume as DCR-PHXC, to serve as placebo
Trial: NCT02303106
Drug: Lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01691976
Drug: Oestrogen Patches
RxNorm normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01691976
Drug: LHRHa
RxNorm normalized name: ALARELIN ACETATE 800 ug in 1 mg INTRAMUSCULAR INJECTION, POWDER, FOR SUSPENSION [LHRHa]
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteinising hormone releasing-hormone agonists (LHRHa)
Trial: NCT02705274
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: 1.25-mg Bevacizumab Intravitreal injection of 1.25 mg Bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.~Other: Deferred panretinal photocoagulation PRP is deferred until failure/futility criteria for intravitreal injection are met.
Trial: NCT01033318
Drug: Comparator: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single oral doses of 100 mg Losartan
Trial: NCT01375608
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.2mg/kg (range, 0.05-0.3 mg/kg) 1-2X/wk for a period of 48 weeks. Dose and frequency will be determined by hematologic toxicity and the achievement of an HbF level of greater the or equal to 20 percent.
Trial: NCT02462993
Drug: Aloe Vera
RxNorm normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local drug delivery of aloe vera gel
Trial: NCT00576472
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Please see detailed description for dosing information and study design.
Trial: NCT01066962
Drug: darunavir/ritonavir QD + raltegravir BID
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD)~ritonavir 100 mg, 1 tablet once daily (QD)~raltegravir 400 mg, 1 tablet twice daily (BID)
Trial: NCT01066962
Drug: darunavir/r QD + tenofovir/emtricitabine QD (fixed dose combination)
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD)~ritonavir 100 mg, 1 tablet once daily (QD)~tenofovir/emtricitabine 245/200 mg, fixed dose combination, 1 tablet once daily (QD)
Trial: NCT01532115
Drug: moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg moxifloxacin (single-dose)
Trial: NCT01771445
Drug: IL-1Ra
RxNorm normalized name: IL-1RA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100mg, s.c, once only
Trial: NCT00439881
Drug: SB-681323
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01675362
Drug: Angiotensin receptor blocker group
RxNorm normalized name: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week
Trial: NCT01353911
Drug: Grazoprevir
RxNorm normalized name: Grazoprevir
DrugBank: Grazoprevir (DB11575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally once daily in AM. Blinded or open-label depending on treatment arm.
Trial: NCT01353911
Drug: Boceprevir
RxNorm normalized name: Boceprevir
DrugBank: Boceprevir (DB08873)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Four 200 mg capsules orally three times daily.
Trial: NCT01353911
Drug: Placebo for Grazoprevir
DrugBank: Grazoprevir (DB11575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally once daily in AM.
Trial: NCT01353911
Drug: Placebo for Boceprevir
DrugBank: Boceprevir (DB08873)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Four capsules orally three times daily.
Trial: NCT01353911
Drug: Peg-interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5 μg/kg/week subcutaneous injection.
Trial: NCT00370552
Drug: Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel, 90 mg/m\^2, given as a 1-hour IV infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab infused over 90 minutes for the first dose, and if well tolerated, over 60 minutes for the second dose. If still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
Trial: NCT01353911
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg to 700 mg orally twice daily.
Trial: NCT01504204
Drug: Adapalene + benzoyl peroxide samples
RxNorm normalized name: adapalene / benzoyl peroxide
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A sample size tube of the study medication, combination adapalene 0.1% plus benzoyl peroxide 2.5% gel, will be provided with instruction on proper application, including demonstration, at the first visit.
Trial: NCT01504204
Drug: Adapalene + benzoyl peroxide from standard tube
RxNorm normalized name: adapalene / benzoyl peroxide
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects are instructed to apply the combination adapalene 0.1% plus benzoyl peroxide 2.5% gel once daily to all affected areas.
Trial: NCT02414048
Drug: Pimonidazole
RxNorm normalized name: Pimonidazole
DrugBank: Pimonidazole (DB12485)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimonidazole will be administered orally and will serve to demarcate the hypoxic areas in the tumour
Trial: NCT01493882
Drug: JNJ-39758979 100 mg/d
DrugBank: JNJ-39758979 (DB18899)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unit = mg, number = 100, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
Trial: NCT00479479
Drug: Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)
RxNorm normalized name: Hydroxycobalamin
DrugBank: Hydroxocobalamin (DB00200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: an intramuscular injection of 400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma, Norway)
Trial: NCT02111590
Drug: Immunoglobulins
RxNorm normalized name: IMMUNOGLOBULINS
DrugBank: Bos taurus colostrum immunoglobulins (DB17753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCIG dosage is individualized for each patient according to previous IVIG dosage
Trial: NCT01437293
Drug: L-dopa / carbidopa / entacapone (LCE)
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For this trial we propose a target dosage of L-dopa / carbidopa / entacapone of 400 mg L-dopa / 100mg carbidopa / 200 mg entacapone, twice daily.
Trial: NCT02100176
Drug: Rotigotine
RxNorm normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rotigotine 2-8 mg/24 h
Trial: NCT03233438
Drug: Dalbavancin
RxNorm normalized name: Dalbavancin
DrugBank: Dalbavancin (DB06219)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.
Trial: NCT00881387
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00881387
Drug: vinorelbine ditartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00974324
Drug: endostar and CHOP
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Endostar (DB11727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: endostar, 7.5m g/m2, intravenous, Day 2-15, repeat every 3 weeks~CHOP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone
Trial: NCT00226330
Drug: Tesaglitazar
RxNorm normalized name: Tesaglitazar
DrugBank: Tesaglitazar (DB06536)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (0.5 or 1 mg)
Trial: NCT00226330
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (15, 30 or 45 mg)
Trial: NCT04133155
Drug: nab paclitaxel plus gemcitabine
RxNorm normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel 125 mg/m2 weekly for 3 weeks, every 4 weeks Gemcitabine 1000 mg/m2 weekly for 3 weeks, every 4 weeks
Trial: NCT00100594
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00100594
Drug: Lamivudine/zidovudine
RxNorm normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00616694
Drug: Actonel
RxNorm normalized name: Actonel
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Actonel 5 mg orally once daily (OD), calcium 500 mg + vitamin D 200 units twice daily (BID)
Trial: NCT01928368
Drug: AMG 282
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose either subcutaneously or intravenously on day 1.
Trial: NCT00854633
Drug: Talactoferrin
RxNorm normalized name: Talactoferrin alfa
DrugBank: Talactoferrin alfa (DB05426)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral, 150 mg/kg twice per day
Trial: NCT01493882
Drug: JNJ-39758979 300 mg/d
DrugBank: JNJ-39758979 (DB18899)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unit = mg, number = 300, form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
Trial: NCT00790569
Drug: nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given transdermally and orally
Trial: NCT00790569
Drug: varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01286103
Drug: Canagliflozin 300 mg once daily and 150 mg twice daily
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment A (one 300-mg tablet once daily for 5 days) followed 10 days later by Treatment B (one 50-mg and one 100-mg tablet twice daily for 5 days) or Treatment B followed by Treatment A.
Trial: NCT01286103
Drug: Canagliflozin 100 mg once daily and 50 mg twice daily
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment C (one 100-mg tablet once daily for 5 days) followed 10 days later by Treatment D (one 50-mg tablet twice daily for 5 days) or Treatment D followed by Treatment C.
Trial: NCT00784537
Drug: ABVD
RxNorm normalized name: Adriamycin, Bleomycin, Vinblastine, Dacarbazine
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~Randomization to Arm A (Observation)
Trial: NCT00784537
Drug: ABVD and Radiotherapy
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~Randomization to Arm B, Radiotherapy, in patients in CR, on the area of initial bulky disease (see above for the definition of nodal and/or mediastinal bulk).
Trial: NCT03437824
Drug: Cyanocobalamin
RxNorm normalized name: Cyanocobalamin
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1,000 mg, Once
Trial: NCT02219503
Drug: Ombitasvir/Paritaprevir/Ritonavir
RxNorm normalized name: ombitasvir/paritaprevir/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet; paritaprevir co-formulated with ritonavir and ombitasvir
Trial: NCT02219503
Drug: Dasabuvir
RxNorm normalized name: Dasabuvir
DrugBank: Dasabuvir (DB09183)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet
Trial: NCT00082381
Drug: Exenatide (AC2993)
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks
Trial: NCT00082381
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: subcutaneous injection, once daily; forced titration to target blood glucose level
Trial: NCT03249103
Drug: NYX-2925
RxNorm normalized name: NYX-2925
DrugBank: NYX-2925 (DB19149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
Trial: NCT04109976
Drug: Bimekizumab
RxNorm normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Study participants will receive bimekizumab at pre-specified time points.
Trial: NCT02025439
Drug: Amantadine
RxNorm normalized name: Amantadine
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01026740
Drug: Ceftobiprole
RxNorm normalized name: Ceftobiprole
DrugBank: Ceftobiprole (DB04918)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single intravenous (i.v.) infusion, 500 mg ceftobiprole administered over 2 hours.